Creative Biolabs

Creative Biolabs Pioneers a New Era in Protein Research and Immunoglobulin Discovery

Through state-of-the-art protein research or trailblazing developments in antibody discovery, Creative Biolabs is further changing the possibilities of therapeutic development.

Industry Context: The Need for Precision Protein Research and Innovative Binders for both Disease Diagnostics & Theranostics

In the fast-moving, progressive biotech world, innovation is what drives advancement—and Creative Biolabs leads the pack, which, fully professed in the edging ribosome analysis and non-IgG therapeutic antibody development, stands ready to empower researchers and industries to address today's most daunting challenges, like cancer, or the rampaging influenza across the entire US since the beginning of 2025.

Ribosome Profiling: Unveiling Translational Control

It has been of great importance over the last decade to learn how proteins are synthesized, the secrets of diseases. Tools such as polysome profiling, which gives snapshots of actively translated mRNA, are acquiring momentum for uncovering mechanisms behind translational control.

"As one of the critical parts of our ribosome analysis solution, we can isolate and analyze polysomes, or clusters of ribosomes that are in the process of translating mRNA, to spotlight post-transcriptional mechanisms (PTMs) that are involved in different biological processes," a scientist at Creative Biolabs introduces, "and we can also raise the game with microarray and RNA-sequencing for high-throughput screening."

Non-IgG Therapeutic Antibody Development: Enabling Full Therapeutic Possibilities

Furthermore, a need for options other than IgG antibodies is increasingly pressing—while IgG antibodies stole the show for so many years, their alternatives, like IgA and IgM, are shifting the dimensions, especially in the case of mucosal immunity and oncology. Creative Biolabs develops and supplies alternative formats of IgA, IgM, IgE, and beyond through:
* Non-IgG Therapeutic Antibody Discovery & Engineering
* Non-IgG Therapeutic Antibody Characterization
* Non-IgG Therapeutic Antibody Production and Purification
* Non-IgG Therapeutic Antibody PK/PD Evaluation
* Non-IgG Therapeutic Antibody Developability Improvement

How to streamline phage display workflows for biopharmaceutical antibody discovery

"Why do non-IgG antibodies matter these days?" The scientist says, "I think is the therapeutic benefit they make when modalities of IgG do not work, for example, targeting novel mechanisms of action and best suited for mucosal immunity and complex diseases."